Regenerative Therapies Library
Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 241–264 of 297
Telomere Shortening Drives Atrial Fibrillation Through VCAM‐1 Mediated Atrial Electrical and Structural Remodeling
Telomere shortening drives atrial fibrillation through VCAM-1 upregulation, which promotes atrial fibrosis and electrical dysfunction. Blocking VCAM-1 reverses these changes and reduces AF susceptibility by 30%, identifying a mechanistic pathway linking cellular aging to arrhythmia risk.
Abinopharm releases AbinoNutra® NMN white paper after FDA reinstatement and clinical evidence
Abinopharm released a white paper on AbinoNutra® NMN following FDA regulatory clarification confirming NMN's legality as a dietary supplement ingredient. A randomized, double-blind clinical trial demonstrated that 60 days of NMN supplementation at doses up to 900 mg increased blood NAD⁺ levels, improved physical performance and endurance, and showed favorable shifts in biological age markers with no serious adverse events.
Pandorum lands $18m to advance ‘programmable regenerative medicine’
Pandorum Technologies closed an $18 million Series B round to advance exosome-based therapies designed to modulate tissue state away from inflammatory and fibrotic conditions toward functional recovery. The platform targets corneal opacity initially, with applications potentially extending across multiple organs affected by inflammatory and degenerative disease.
Single‐Cell Profiling Reveals RAB13+ Endothelial Cells and Profibrotic Mesenchymal Cells in Aged Human Bone Marrow
Single-cell analysis reveals that aging bone marrow undergoes distinct cellular remodeling: endothelial cells develop prothrombotic and mitochondrial dysfunction, while a novel RAB13+ arterial endothelial subset emerges alongside expansion of profibrotic mesenchymal cells. These cellular shifts directly impair the marrow's capacity to support healthy blood cell production and tissue maintenance, establishing specific molecular targets for intervention.
Celularity secures $35m license deal to back longevity strategy
Celularity licensed its placental-derived biomaterials portfolio for up to $35 million in non-dilutive capital, allowing the company to redirect resources toward cell therapies targeting senescence, inflammation, and tissue degeneration. This repositioning reflects a strategic shift from broad biomaterials commercialization to targeted longevity interventions.
RNA Recycling Extends Lifespan
RNASEK, an enzyme that degrades circular RNA accumulation in cells, extends lifespan in model organisms by removing a form of molecular waste that accelerates aging. This identifies a specific degradation pathway central to cellular longevity.
CFTR Protein Blocks Heart Cell Aging Through Calcium Control
CFTR, a protein typically studied for its ion channel function, operates through a secondary mechanism to prevent cardiomyocyte senescence by reducing mitochondrial oxidative stress. The USP45 enzyme stabilizes CFTR through deubiquitination, which enhances calcium regulation and protects heart cells from age-related dysfunction implicated in atrial fibrillation and cardiovascular disease.
Unlimited Bio registers dual gene therapy trial
Unlimited Bio initiated a Phase 1/2a trial combining AAV9-Follistatin and VEGF plasmid gene therapies to address age-related muscle decline, marking the first registered clinical study to combine these two approaches. The dual-therapy strategy targets both muscle growth signaling and vascular support, with safety and functional outcomes tracked over 12 months in adults aged 45 to 75.
Pretzel Therapeutics presents PX578 data supporting POLG disease treatment
PX578, a first-in-class small molecule activator of mitochondrial DNA polymerase gamma, demonstrated preclinical efficacy in restoring mitochondrial DNA levels and cellular energy production across multiple POLG disease models. The compound addresses the underlying genetic defect in mitochondrial DNA depletion syndromes, for which no disease-modifying treatments currently exist.
Engineering longevity with the ZEUGMA hyperbaric chamber
Hyperbaric oxygen therapy, traditionally confined to clinical medicine, is being deployed in performance and longevity settings through chambers like ZEUGMA, which operate at pressures enabling oxygen to dissolve into plasma at concentrations far exceeding atmospheric levels. The mechanism addresses tissue oxygen delivery and cellular repair, though evidence for durable benefits in healthy individuals remains under investigation.
Nuritas brings PeptiStrong clinical momentum to Vitafoods
Nuritas is conducting a 30-day randomized controlled trial comparing PeptiStrong (a fava bean-derived peptide) plus whey protein against whey protein alone in adults aged 60–85, with grip strength as the primary outcome and secondary measures including gait speed, balance, and inflammatory markers. The trial addresses a direct mechanism relevant to aging: preserving muscle function and mass in older populations.
Clonal hematopoiesis boosts response to immune checkpoint therapy
Clonal hematopoiesis—the age-related expansion of mutant blood cell populations—enhances response to immune checkpoint inhibitors in cancer patients. This unexpected finding reframes a hallmark of aging as potentially protective in the context of immunotherapy, with implications for how we interpret immune aging and treatment efficacy.
Gut Bacteria Strain Reverses Age-Related Lung Fibrosis
A Lactobacillus strain (L9) found in centenarians reduces pulmonary fibrosis in aging mice by 30% through a metabolite-signaling pathway that suppresses collagen synthesis. The mechanism operates through the JNK signaling cascade and senescence-associated inflammatory cytokines, establishing a direct gut-to-lung biochemical axis relevant to fibrotic disease prevention.
GLP-1 joint injection shows promise for knee osteoarthritis
4Moving Biotech has enrolled 129 patients in a Phase 2a trial of 4P004, a GLP-1 receptor agonist delivered directly into the knee joint to reduce inflammatory mechanisms in osteoarthritis. The trial will measure pain reduction and synovial tissue changes over 12 weeks, with results expected by end of 2026.
Cellular silencing bypass extends gene therapy durability
Houdini Bio has developed a machine learning platform that redesigns therapeutic DNA to evade the HUSH complex, a cellular mechanism that silences foreign genetic material. This approach extends gene therapy durability while reducing required doses, with particular relevance for neurodegenerative diseases where sustained expression in long-lived neurons is critical to therapeutic outcome.
NB4168 bioavailability edge for rare disease clinical trials
Niagen Bioscience is advancing NB4168, an oral candidate for Ataxia Telangiectasia, through preclinical development with contract partner Evotec. Nonclinical studies show NB4168 achieves substantially higher blood exposure than NR chloride, positioning the compound for IND submission and clinical evaluation.
Myostatin inhibitors preserve muscle mass during GLP-1 weight loss
NorthStrive Biosciences has filed patent applications for two therapeutic candidates designed to preserve lean muscle mass during GLP-1-mediated weight loss and other catabolic states. The compounds target myostatin and activin A pathways through peptide and probiotic delivery mechanisms, addressing a significant gap in current obesity pharmacotherapy where muscle loss accompanies fat loss.
Translation Attenuation Extends Lifespan and Protects Neurons
Atypical tetracyclines extend lifespan and protect neurons from ferroptotic damage by reducing protein synthesis through mechanisms independent of their antibiotic activity. This identifies translation attenuation as a pharmacologically targetable pathway for longevity and neuroprotection across multiple organism models.
Liver Protein Signatures Outpredict Mortality Risk in Aging
Circulating protein signatures enriched in liver and immune markers predict all-cause mortality in older adults with superior performance to conventional clinical risk factors. A 20-protein score achieved C-index 0.81 for mortality discrimination and validated consistently across independent cohorts, establishing plasma proteomics as a scalable biomarker platform for biological age stratification.
Multiomic single-cell perturbation screens reveal critical lncRNA regulators of senescence
A systematic screen of 32 aging-associated long non-coding RNAs identified HOTAIRM1 as a critical regulator of DNA repair pathways, with restoration of HOTAIRM1 in aged mouse lungs reducing fibrosis. This work establishes lncRNA regulation as a targetable mechanism in cellular senescence.
Progeria Research Reveals Cardiovascular Aging Mechanisms
Progeria research has matured to the point where therapeutic strategies are moving from basic science toward clinical implementation. Understanding the molecular mechanisms driving accelerated aging in Hutchinson–Gilbert progeria syndrome offers direct insights into cardiovascular pathology and age-related tissue degeneration in the general population.
FFAR4 Activation Reverses Kidney Senescence in Aging
Omega-3 polyunsaturated fatty acids reduce cellular senescence in kidney tissue through FFAR4 receptor activation, improving filtration function and reducing fibrosis in aging and diseased kidneys. This mechanism explains why previous clinical trials showed inconsistent results and identifies a specific molecular target for renal protection.
Japanese startup makes hair follicle regeneration breakthrough
OrganTech has identified a three-cell configuration—including a previously uncharacterized mesenchymal cell type—capable of regenerating fully functional hair follicles that maintain cycling and production in vivo. This work establishes a cellular blueprint for hair follicle regeneration and suggests broader applications for complex tissue reconstruction.
Liver Regeneration Shifts From Theory to Tissue Reconstruction
Regenerative medicine is advancing from theoretical to practical application in liver repair, with organoid technology and engineered tissues now enabling researchers to reconstruct damaged liver tissue and potentially restore function. This represents a fundamental shift from managing liver decline to actively rebuilding organ structure—a capability with significant implications for extending healthspan in aging populations.